Semi-Solid and Stability Troubleshooting
Semi-solid dosage forms present their own characteristic set of manufacturing and stability challenges rooted in their emulsified or gelled physical...
Semi-solid dosage forms present their own characteristic set of manufacturing and stability challenges rooted in their emulsified or gelled physical structure. Phase separation in creams, observed as visible splitting of the oil and aqueous phases, most commonly results from insufficient emulsifier concentration or from temperature excursions during manufacture or storage that exceed the thermal stability range of the emulsifying system, and is addressed by increasing the concentration of a higher Hydrophile-Lipophile Balance emulsifier, incorporating a co-stabiliser such as hydroxypropyl cellulose to reinforce the interfacial film, or tightening control of manufacturing temperature during the emulsification process.
pH drift observed over the course of storage typically reflects inadequate buffer capacity within the formulation relative to the chemical reactivity of the drug and excipients, or interaction between the formulation and its container closure system, and is remediated by increasing buffer concentration or by verifying compatibility between the formulation and the intended packaging material. Loss of viscosity in gel formulations over storage time frequently indicates gradual polymer degradation, often catalysed by ionic interaction between the gelling polymer and trace metal ions present in the formulation or introduced from the manufacturing environment, and is addressed by substituting a non-ionic gelling polymer less susceptible to such interaction, avoiding the inclusion of electrolyte excipients where formulation flexibility permits, or incorporating a chelating agent such as ethylenediaminetetraacetic acid to sequester interfering metal ions.
Microbial contamination detected during stability testing generally indicates preservative system failure, whether through inherent inadequacy of the preservative concentration selected, incompatibility between the preservative and other formulation components that reduces its effective free concentration, or lapses in manufacturing hygiene, and troubleshooting accordingly requires re-evaluation of preservative efficacy in accordance with USP <51>, consideration of an increased preservative concentration such as an elevated paraben level, and a thorough review of manufacturing environmental controls. Drug precipitation observed during storage of a liquid formulation typically indicates that the drug's solubility limit within the vehicle has been exceeded, whether due to a slow crystallisation process from an initially supersaturated or metastable solution, or due to a temperature-dependent solubility decline during cold storage or transport, and is addressed through the addition of a solubilising agent, a reduction in the target drug concentration to provide a greater solubility safety margin, or tighter control of the storage temperature range specified for the product.